Keyphrases
Gynecologic Oncology
66%
Endometrial Cancer
54%
Ovarian Cancer Patients
46%
Ovarian Cancer
43%
Wound Complications
40%
High-grade Serous Ovarian Cancer (HGSOC)
32%
Gynecological Cancer
30%
Overall Survival
28%
Tumor Cells
28%
Tumor
26%
Oncology Patients
25%
Recurrent Endometrial Cancer
24%
Tumor Microenvironment
23%
AXL Inhibition
22%
Patient-derived Organoids
22%
Complication Rate
22%
COVID-19 Pandemic Impact
22%
Palliative Care
22%
Excision
22%
Platinum-based Chemotherapy
20%
Organoids
19%
Patient-derived
19%
Survival Outcomes
17%
Gynecologic Malignancies
17%
Immunohistochemistry
16%
RAD51 Foci
16%
Treatment Options
16%
Molecular Targeted Therapy
15%
Predictive Biomarker
15%
Cancer Patients
15%
Hysterectomy
15%
Vulvar
14%
Ovarian Organoid
14%
Oncology Care
14%
Primary Tumor
14%
Society of Gynecologic Oncology
14%
Gynecologic Surgery
14%
Cancer Types
14%
Platinum-free Interval
14%
Tumor Burden
14%
Vertical Incision
14%
Paclitaxel
13%
Chemotherapy Response
13%
Homologous Recombination Deficiency
13%
Ovarian Metastasis
13%
Chemotherapy Resistance
13%
PARP Inhibitor (PARPi)
13%
Pembrolizumab
13%
Perioperative Antibiotics
12%
Prophylactic Antibiotics
12%
Medicine and Dentistry
Ovarian Cancer
100%
Gynecological Oncology
66%
Uterine Cancer
51%
Neoplasm
50%
Organoid
44%
Wound Complication
39%
Malignant Neoplasm
25%
Female Genital Tract Cancer
25%
Metastatic Carcinoma
25%
Tumor Cell
25%
COVID-19
22%
Symptomatic Treatment
22%
Frailty Index
22%
Overall Survival
21%
Cancer
20%
Cell Line
19%
Diseases
18%
Homologous Recombination
17%
Recurrent Disease
16%
Patient Referral
16%
Hysterectomy
15%
Biological Marker
15%
Gynecological Surgery
14%
Immunohistochemistry
14%
DNA Repair
14%
Antibiotics
14%
Incision
13%
Poly ADP Ribose Polymerase
13%
Pembrolizumab
13%
Frailty
13%
Paclitaxel
12%
Randomized Controlled Trial
12%
Mesothelial Cell
12%
DNA Damage
11%
Primary Tumor
11%
In Vitro
11%
Acute Chest Syndrome
11%
Immunofluorescence Test
11%
Direct Oral Anticoagulant
11%
Chlamydia Trachomatis
11%
Adipose Tissue
11%
Visceral Fat
11%
Gestagen
11%
Subcutaneous Fat
11%
Sickle Cell
11%
Immunotherapy
11%
Primary Health Care
11%
Cytoreductive Surgery
11%
End of Life Care
11%
Vulvar Cancer
11%